<DOC>
	<DOCNO>NCT01397838</DOCNO>
	<brief_summary>Recent study show inhibition Aquaporine-9 channel may ameliorate bone degradation process . Pro-bone AQ - 9 channel inhibitor . This study design evaluate safety Pro-bone .</brief_summary>
	<brief_title>Safety Study Oral Pro-boneTM , Administered Post Menopausal Osteopenic Women</brief_title>
	<detailed_description />
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<criteria>BMD measure DEXA screening , range ( 1 ) ( 2.5 ) SD normal value . At least 12 month spontaneous amenorrhea least 6 week postsurgical bilateral oophorectomy without hysterectomy . Study participant take estrogen alone estrogen/progestin contain drug product . Study participant take antiosteoporosis treatment list one year . The follow washout period baseline assessment make subject previously estrogen alone estrogen/progestin contain product : 1 . 8 week longer prior use estrogen and/or progestin product . 2 . 6 month longer prior progestin injectable drug therapy . 3 . Women 45 65 year ( inclusive ) age . 4 . BMI 2230 ( inclusive ) 5 . Nonsmoking ( declaration ) period least 6 month . 6 . Subjects able adhere visit schedule protocol requirement available complete study . Subjects provide write informed consent . Women documentation positive screening mammogram ( obtain screen within 9 month study enrolment ) abnormal clinical breast examination prior enrolment clinical study . Known history significant medical disorder , investigator 's judgment contraindicate administration study medication . Any clinically significant abnormality , upon physical examination clinical laboratory test , screen visit . Known history drug alcohol abuse accord participant declaration screen visit . Any acute medical situation ( e.g . acute infection ) within 48 hour study start , consider significance Principal Investigator . Subjects noncooperative unwilling sign consent form .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Osteopenia</keyword>
</DOC>